Childhood and adolescent cancers

Sulupass

Post-Authorisation Safety Study of Paediatric Patients Initiating Selumetinib: A Multiple-Country Prospective Cohort Study

Open at Paris since : 23/05/2022
Target : Child
Phase : Phase III

Trial description

The primary objective of this study is:;À;To characterise the safety of selumetinib, including long-term safety, in paediatric patients with NF1-related symptomatic, inoperable PN, 8 to < 18 years old who have not reached Tanner Stage V at the start of selumetinib treatment.;The secondary objective of this study is:;À;To describe the paediatric population 3 to < 18 years old with NF1-related symptomatic inoperable PN who start selumetinib in routine clinical practice

Url of the trial

Main investigator

ISABELLE AERTS

Médecin

Contact